China F&B Update: Bubble Tea Chain IPOs Signal Market Growth — Key Takeaways

Date:

Share post:

China F&B Update: Bubble Tea Chain IPOs Signal Market Growth — Key Takeaways

China’s bubble tea market is boiling over. In the first quarter of 2025 alone, Mixue Group (蜜雪冰城, Mìxuě Bīngchéng) raised USD 444 million in its Hong Kong IPO, while Chagee (霸王茶姬, Bàwáng Chájī) filed for a USD 300–500 million listing — pushing the total capital raised by bubble tea chains past USD 1 billion in just 12 months. Three major players now trade publicly, and at least two more are expected to list by year-end. For foreign executives tracking China’s F&B sector, this wave of IPOs signals deep structural growth, not just fleeting consumer hype.

This article distills the key takeaways from the bubble tea IPO surge: who went public, why the market is expanding, and what it means for foreign investors looking to enter or scale in China’s beverage space.

The IPO Wave: Mixue, Chagee, and the Race for Scale

Since 2024, China’s 新茶饮 (new-style tea beverages, xīn cháyǐn) sector has seen an unprecedented flurry of public listings. 蜜雪冰城 (Mixue, Mìxuě Bīngchéng) — the country’s largest bubble tea chain by store count — listed in Hong Kong on March 3, 2025, pricing at HKD 202.50 per share. Its IPO was oversubscribed 17 times, reflecting strong institutional demand. Chagee followed with a confidential filing in April 2025, aiming for a valuation of USD 5 billion. Meanwhile, 奈雪的茶 (Nayuki, Nài Xuě de Chá), which listed in 2021, and 喜茶 (Heytea, Xǐ Chá), still privately held, remain market bellwethers.

The table below compares the four major chains across store count, average price, and revenue — offering a snapshot of the market’s diversity.

Chain IPO Status Stores (end 2024) Avg. Price (RMB) 2024 Revenue (RMB bn)
Mixue Listed March 2025 (HK) 36,000+ 6–8 24.8
Chagee Filed April 2025 (HK) 6,000+ 15–20 8.5
Heytea Private 3,500+ 25–30 5.2
Nayuki Listed 2021 (HK) 1,800+ 28–35 4.1

Key takeaway: The market is bifurcating. Mixue dominates the 下沉市场 (sinking market, xiàchén shìchǎng) — lower-tier cities where price sensitivity is high — while Chagee, Heytea, and Nayuki compete in premium urban segments. Each model is proving IPO-worthy, indicating that both volume and value paths are viable.

Key Growth Drivers: From Tier 1 to County-Level Cities

Why are bubble tea chains flooding public markets? Three numbers tell the story. First, China’s bubble tea market exceeded RMB 350 billion (USD 48 billion) in retail sales in 2024, up 18% year-on-year. Second, consumption per capita in fourth- and fifth-tier cities grew 32% in 2024 — triple the growth rate in first-tier cities. Third, the number of bubble tea stores nationwide surpassed 450,000 in 2024, with Mixue alone adding 10,000 new stores in a single year.

These statistics underscore a deep shift. Rising disposable incomes in inland provinces, coupled with improved logistics and digital ordering infrastructure, have turned county-level towns into profit centers. For example, Mixue’s stores in rural Anhui and Henan average daily sales of RMB 1,200–1,500, only slightly below the national average of RMB 1,800. The unit economics work because Mixue controls the entire supply chain — from processing tea leaves to manufacturing plastic cups — squeezing costs to maintain single-digit price points.

Foreign food-and-beverage executives should note: the bubble tea IPO wave reflects more than brand popularity. It signals that China’s domestic F&B companies have matured to the point where they can scale profitably outside Tier 1 cities — a benchmark many Western chains still struggle to meet.

What This Means for Foreign F&B Investors

For foreign companies eyeing China’s beverage market, the bubble tea IPO boom offers three lessons. First, localization is non-negotiable. Mixue’s success hinges on its “community-centric” model — small stores (30–50 sqm) in residential neighborhoods, often run by franchisees who live above the shop. Foreign brands accustomed to flagship stores in prime malls may find that model difficult to replicate.

Second, supply chain vertical integration is a competitive moat. Mixue operates its own tea plantation, fruit processing plants, and distribution fleet. That’s how it keeps a cup at RMB 6 and still achieves gross margins of 58%. Foreign entrants without similar infrastructure will face margin pressure.

Third, the IPO pipeline itself creates an opening. As Chagee and others go public, they will likely expand franchise networks more aggressively, intensifying competition. However, they also raise consumer expectations for innovation — creating a market for niche products (e.g., sugar-free, organic, or functional teas) that foreign brands could fill. A joint venture with a local chain or a minority stake in a pre-IPO player might be a faster route than building from scratch.

Foreign investors should also monitor regulatory shifts. The 食品安全法 (Food Safety Law, shípǐn ānquán fǎ) is being updated in 2025 to tighten online ordering standards — affecting delivery-centric bubble tea brands. Mixue has already invested in tamper-proof packaging and real-time temperature monitoring for deliveries. Foreign firms must align with these evolving standards to avoid costly penalties.

NEXT STEPS: 3 Recommendations for Foreign F&B Executives

  1. Understand China’s F&B regulatory landscape. Review our detailed guide on F&B licensing and food safety compliance in China — critical before any market entry.
  2. Evaluate franchise vs. self-operated models. See our comparison of franchise versus wholly foreign-owned enterprise (WFOE) structures for beverage chains.
  3. Assess supply chain localization. Read our case study on localizing raw material sourcing and cold-chain logistics — a key factor in Mixue’s profitability.

— China Gateway 360 —
Remote China market entry support, built around execution.

Related articles

How a Foreign Biotech Startup Entered China’s Precision Medicine Market: Case Study

How a Foreign Biotech Startup Entered China's Precision Medicine Market: Case Study In 2023, NovaOnco Therapeutics, a US-based AI biotech startup, exe

How Legend Biotech Secured FDA Approval for CAR-T Therapy: Case Study

How Legend Biotech Secured FDA Approval for CAR-T Therapy: A China Biotech Case Study This case study examines how Legend Biotech (传奇生物, Legend Biotec

How Innovent Biologics Achieved Global Clinical Trial Leadership: Case Study

How Innovent Biologics Achieved Global Clinical Trial Leadership: Case Study body{font-family:'Segoe UI',Tahoma,Geneva,Verdana,sans-serif;line-height:

How BeiGene Built a Billion-Dollar Biotech in China: Case Study

How BeiGene Built a Billion-Dollar Biotech in China: Case Study How BeiGene Built a Billion-Dollar Biotech in China: Case Study The story of BeiGene's